Adcock Ingram Holdings Ltd AIP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ZAC 5,550.00
- Day Range
- ZAC 5,550.00–5,587.00
- 52-Week Range
- ZAC 4,958.00–6,148.00
- Bid/Ask
- ZAC 5,500.00 / ZAC 5,587.00
- Market Cap
- ZAC 841.06 Bil
- Volume/Avg
- 18,788 / 79,616
Key Statistics
- Price/Earnings (Normalized)
- 9.71
- Price/Sales
- 0.96
- Dividend Yield (Trailing)
- 4.50%
- Dividend Yield (Forward)
- 4.50%
- Total Yield
- 10.22%
Company Profile
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,549
- Website
- https://www.adcock.com
Comparables
Valuation
|
Metric
|
AIP
|
REN
|
BVT
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.71 | — | 11.86 |
Price/Book Value | 1.53 | 2.27 | 2.35 |
Price/Sales | 0.96 | 51.03 | 0.66 |
Price/Cash Flow | 8.73 | — | 7.01 |
Price/Earnings
AIP
REN
BVT
Financial Strength
|
Metric
|
AIP
|
REN
|
BVT
|
|---|---|---|---|
Quick Ratio | 0.94 | 0.42 | 0.69 |
Current Ratio | 1.92 | 0.60 | 1.09 |
Interest Coverage | 16.26 | — | 4.50 |
Quick Ratio
AIP
REN
BVT
Profitability
|
Metric
|
AIP
|
REN
|
BVT
|
|---|---|---|---|
Return on Assets (Normalized) | 10.68% | — | 6.26% |
Return on Equity (Normalized) | 16.33% | — | 20.73% |
Return on Invested Capital (Normalized) | 15.87% | — | 11.32% |
Return on Assets
AIP
REN
BVT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Skrjxcwwbz | Lfzjm | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Qtrykdwbqy | Rvnzh | $70.8 Bil | |
HLN
| Haleon PLC ADR | Bksxkxrl | Mmvm | $37.7 Bil | |
VTRS
| Viatris Inc | Gwfzljvc | Nknk | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Sbhllbpm | Qkx | $12.5 Bil | |
CTLT
| Catalent Inc | Bzqkqtvzn | Vtknsvy | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Rpzxcdlc | Qwr | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Jnvklzdvk | Xgdw | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mpkwvbjkf | Ldlylb | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Plypkwlty | Kztrm | $2.9 Bil |